197 related articles for article (PubMed ID: 21187600)
1. [Anti-sclerostin antibodies].
Okazaki R
Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
3. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the inhibitor: a new route to bone anabolism.
Jilka RL
J Bone Miner Res; 2009 Apr; 24(4):575-7. PubMed ID: 19335216
[No Abstract] [Full Text] [Related]
5. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
Soen S
Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
[TBL] [Abstract][Full Text] [Related]
6. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
7. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
9. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Padhi D; Jang G; Stouch B; Fang L; Posvar E
J Bone Miner Res; 2011 Jan; 26(1):19-26. PubMed ID: 20593411
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats.
Tian X; Setterberg RB; Li X; Paszty C; Ke HZ; Jee WS
Bone; 2010 Sep; 47(3):529-33. PubMed ID: 20561907
[TBL] [Abstract][Full Text] [Related]
11. [Bone and Nutrition. Sclerostin and bone metabolism].
Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
[TBL] [Abstract][Full Text] [Related]
12. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
13. [Hormones and osteoporosis update. Mechanisms of anabolic and catabolic effects of PTH on bone].
Kobayashi T
Clin Calcium; 2009 Jul; 19(7):911-8. PubMed ID: 19567985
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin monoclonal antibodies on bone metabolism and fracture healing.
Gamie Z; Korres N; Leonidou A; Gray AC; Tsiridis E
Expert Opin Investig Drugs; 2012 Oct; 21(10):1523-34. PubMed ID: 22849579
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin, an osteocytes-derived bone-forming inhibitor.
Włodarski KH; Galus R; Brodzikowska A; Włodarski PK
Pol Orthop Traumatol; 2013 Jul; 78():151-4. PubMed ID: 23820854
[TBL] [Abstract][Full Text] [Related]
16. [Cytokines in bone diseases. Wnt signal and excessive bone formation].
Hosoi T
Clin Calcium; 2010 Oct; 20(10):1526-31. PubMed ID: 20890035
[TBL] [Abstract][Full Text] [Related]
17. Does osteocytic SOST suppression mediate PTH bone anabolism?
Kramer I; Keller H; Leupin O; Kneissel M
Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
19. Wnt signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
Löwik CW; van Bezooijen RL
J Musculoskelet Neuronal Interact; 2006; 6(4):357. PubMed ID: 17185823
[No Abstract] [Full Text] [Related]
20. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
